London-based Hypervision Surgical recently secured £6.5 million in seed funding to develop cutting-edge technology for enhanced surgical and patient safety. The funding round was led by renowned European and American HealthTech investors, including HERAN Partners, Redalpine (also backed 9fin), LifeX Ventures, and ZEISS Ventures.
Industry Veteran Martin Frost CBE joins Hypervision Surgical’s Board of Directors
Martin Frost CBE, Founder and former CEO of CMR Surgical, joined Hypervision Surgical’s board of directors. Frost’s exceptional contributions to surgical robotics led to the global recognition of CMR Surgical as a unicorn. He was awarded a CBE in Queen’s Birthday Honours 2020 for his remarkable achievements.
Accelerating development and regulatory clearance
The funding will drive the development of Hypervision Surgical’s advanced vision technology and support regulatory clearance in the United States and Europe. Strategic collaborations with leading surgeons, renowned surgical centers, and industry partners on both sides of the Atlantic will ensure successful market launch and seamless integration into clinical practice.
Transforming surgical precision with Hyperspectral Intelligence
Hypervision Surgical’s innovative hyperspectral imaging software enables surgeons to distinguish between healthy and infected tissue with ease. By providing precise measurements and tissue property information, their technology empowers surgeons to make confident decisions, improving patient outcomes and reducing complications.
Expanding team and seeking strategic partnerships
Hypervision Surgical, founded by researchers and clinicians as a spin-off from King’s College, plans to expand its team and operations. The company aims to establish strategic partnerships in surgical robotics, surgical microscopy, and surgical vision. With a focus on operations, sales, and technology, Hypervision Surgical is poised for further growth and impact in the field of surgical innovation.
Raf Roelands, Investment Director at HERAN Partners, stated, “Hypervision Surgical’s hardware-agnostic solution has the potential to redefine the standard of care in surgical imaging across various procedures, from open to minimally invasive, robotics, and microscopic surgeries.”
Daniel Dillinger, Investment Manager at Redalpine, emphasised, “Hypervision Surgical’s objective tissue characterisation and analytics platform is uniquely positioned to drive surgical decision-making and address critical unmet needs in the growing field of minimally invasive surgery.”
Iñaki Berenguer, Founding Partner at LifeX Ventures, highlighted the potential impact, stating, “The innovation in AI-powered vision systems, with simplified deployment in hospitals, holds the key to significantly improving the lives of millions of patients undergoing critical surgeries. Hypervision Surgical has the necessary ingredients to lead in this category.”
“We are thrilled to have Martin Frost join our board of directors,” said Michael Ebner. “His unparalleled expertise in building and scaling surgical technology ventures will be invaluable as we navigate the next phase of Hypervision Surgical’s growth and commercialisation efforts.”